pyrazines has been researched along with Cancer of Salivary Gland in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimori, T; Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Uchida, D | 2 |
| Laurie, SA; Licitra, L | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Kimpe, M; Nuyts, S; Prenen, H | 1 |
| Adachi, M; Gohda, H; Harada, K; Ikeda, Y; Kawamata, H; Kinoshita, M; Nakashiro, K; Nishida, T; Ono, K; Sato, M; Yoshida, H | 1 |
| Hamano, H; Hino, S; Kawamata, H; Miwa, Y; Nakashiro, K; Omotehara, F; Sato, M; Uchida, D; Yoshida, H | 1 |
| Hino, S; Kawamata, H; Nakashiro, K; Omotehara, F; Sato, M; Uchida, D; Yoshida, H | 1 |
3 review(s) available for pyrazines and Cancer of Salivary Gland
| Article | Year |
|---|---|
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
5 other study(ies) available for pyrazines and Cancer of Salivary Gland
| Article | Year |
|---|---|
Vesnarinone, a differentiation inducing drug, directly activates p21(waf1) gene promoter via Sp1 sites in a human salivary gland cancer cell line.
Topics: Antineoplastic Agents; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Electrophoretic Mobility Shift Assay; Gene Deletion; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Luciferases; Plasmids; Promoter Regions, Genetic; Pyrazines; Quinolines; Salivary Gland Neoplasms; Sp1 Transcription Factor; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2002 |
Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, vesnarinone in a human salivary gland cancer cell line.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Plasmids; Pyrazines; Quinolines; RNA, Messenger; Salivary Gland Neoplasms; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Pyrazines; Quinolines; Salivary Gland Neoplasms; Transforming Growth Factor beta; Tumor Cells, Cultured | 1997 |
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Clone Cells; DNA, Antisense; DNA, Complementary; Gene Expression Regulation, Neoplastic; Humans; Leucine Zippers; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Promoter Regions, Genetic; Pyrazines; Quinolines; Recombinant Fusion Proteins; Repressor Proteins; RNA, Messenger; RNA, Neoplasm; Salivary Gland Neoplasms; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1998 |
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Humans; Neoplasm Proteins; Oligonucleotides, Antisense; Pyrazines; Quinolines; Repressor Proteins; RNA, Messenger; Salivary Gland Neoplasms; Transcription Factors; Tumor Cells, Cultured; Up-Regulation | 1998 |